Daily Stock List
North American Oil and Gas Corp. (CLDD)
Winning Penny Stock Picks, WePickPennyStocks, Super Nova Stock Picks, PennyStockPickReport, PennyStockPickAlert, PennyStockMoneyTrain, Liquid Tycoon, TheLightningPicks, BeaconEquityResearch, Stock Preacher, InvestorSoup, Stock Roach, Penny Stocks Finder, and MicroStockProfit reported this week on North American Oil and Gas Corp. (CLDD), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
North American Oil and Gas Corp. is an oil and gas enterprise that lists on the OTC Bulletin Board. The Company focuses on the prolific San Joaquin Basin, onshore California. North American Oil and Gas has existing foundation assets targeting exploration and exploitation of high impact oil and gas projects located near infrastructure and existing discoveries. The Company has their corporate headquarters in Ventura, California.
North American Oil and Gas management has extensive industry experience in the San Joaquin Basin. The Company's objective is to become a significant oil and gas producer in California through concentrating on a balanced portfolio of multiple projects targeting production enhancement opportunities and moderate to high impact exploration located near existing discoveries. Pertaining to their exploration and development strategy, the Company will focus on organic growth via the drill bit. Their business strategy is to continue to pursue asset acquisitions through a combination of ground floor acreage acquisitions and asset deals to build reserves and production.
At present, North American Oil and Gas' portfolio in the San Joaquin Basin consists of three projects that they currently operate. They will pursue an integrated strategy of exploration and development drilling in the San Joaquin Basin. This will include farm-in opportunities, farm-out opportunities, further land acquisitions, as well as swaps of property interests.
Concerning two of their Projects, the Tejon Extension Prospect is approximately 20 miles south of Bakersfield, California, in the southernmost part of the San Joaquin Valley. The Company is the operator and they have a Working Interest (WI) of 75 percent (Net Revenue Interest (NRI) 60 percent). The acreage position is 320 gross acres.
Their Tejon Footwall Prospect is approximately 20 miles south of Bakersfield, California, in the southernmost part of the San Joaquin Valley. It is immediately adjacent and to the east of their Tejon Extension property. The Company is a Non-Operator here. Their WI is 21.25 percent (NRI 17 percent). The acreage position is 3448 gross acres.
Earlier this month, North American Oil and Gas announced the spudding of the Pass Exploration 77-20 exploration well at their Tejon Extension Prospect. The well will test a prospective oil area between the Tejon and Tejon North Fields, approximately 30 miles southwest of Bakersfield. The primary objective of the well is the Olcese sand reservoirs, which are productive near the prospect. The expectation is that the well will take approximately 12 days to reach a total depth of 7500 ft.
North American Oil and Gas Corp. (CLDD), closed Friday's trading session at $0.90, up 19.68%, on 28,150 volume with 14 trades. The average volume for the last 60 days is 399 and the stock's 52-week low/high is $0.25/$1.14.
Cyalume Technologies Holdings, Inc. (CYLU)
SmallCapVoice and SeriousTraders reported previously on Cyalume Technologies Holdings, Inc. (CYLU), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Cyalume Technologies Holdings, Inc. designs and manufactures non-pyrotechnic Tactical Products and Training Solutions for worldwide militaries and law enforcement agencies, and for certain safety markets. The Company is the exclusive supplier to the U.S. and NATO-country militaries for all of their chemical light needs. Cyalume Technologies lists on the OTC Bulletin Board. The Company has their corporate headquarters in West Springfield, Massachusetts.
Cyalume Technologies operates manufacturing facilities in the United States and France. By way of their subsidiary, Cyalume Specialty Products, they also manufacture specialty chemical components for diverse markets. Cyalume Technologies designs and manufactures premier quality Chemical Lighting products preferred by the world's top military and law enforcement organizations, to the most sophisticated Non-Pyrotechnic Battlefield Effects Simulators (BES) and Improvised Explosive Device (IED) Simulators.
An overwhelming majority of military forces globally uses Cyalume ChemLights™, millions of times annually. Cyalume® lights are waterproof, durable, self-contained and always ready for use. ChemLights™ can be air dropped with personnel or equipment, ejected into the ocean or shot out of a 40mm gun.
Cyalume Technologies has a strategic agreement with Fiocchi Ammunition to develop and market the Chemical Tracer, the world's first non-pyrotechnic shotgun tracer. The Chemical Tracer creates a daytime visible trace that travels with the cloud of the shot allowing shooters to instantly determine their accuracy and consequently correct their aim. Fiocchi Ammunition is a world leader in the field of small-caliber ammunition.
In addition, Cyalume is the sole provider of chemiluminescent light sticks to the United States Military, NATO, and FEMA. They offer industrial grade SnapLights, a reliable way to see and be seen. Cyalume SnapLights are tested, proven, and recommended for Utilities (Flameless, Waterproof lights for indoors and out); Hotels (Evacuation lights, room and hallway lighting during power outages), and Businesses (Work lighting during power outages, evacuation lights).
This week, Cyalume Technologies announced preliminary expectations for the 2012 fourth quarter and therefore the full year, as well as their initial outlook for 2013. The Company expects revenues for the 2012 fourth quarter to be approximately $12 million, or 40 percent ahead of revenues reported in the 2011 fourth quarter. This represents a 19 percent improvement, compared to the 2012 third quarter revenues of $10.1 million.
They expect 2012 fourth quarter net cash provided by operating activities and Adjusted EBITDA to exceed the $0.8 million and the $1.0 million, respectively, reported for the fourth quarter of 2011. Therefore, for 2012, the expectation is that revenues will be approximately $39 million, a 12 percent increase from 2011 revenues of $34.7 million. Concerning 2013, excluding any acquisitions, the Company expects additional improvement of their top and bottom line in comparison to 2012.
Cyalume Technologies Holdings, Inc. (CYLU), closed Friday's trading session at $1.40, up 11.11%, on 56,880 volume with 21 trades. The average volume for the last 60 days is 19,060 and the stock's 52-week low/high is $0.50/$5.95.
Lithium Exploration Group, Inc. (LEXG)
Greenbackers, AwesomePennyPicks, Epic Stock Picks, AllPennyStocks, TheStockfather, Monster OTC, SmallCapVoice, WallStreet Profits, and Bold Stocks reported earlier on Lithium Exploration Group, Inc. (LEXG), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Scottsdale, Arizona, Lithium Exploration Group, Inc. is an exploration and development company focusing on the acquisition and development potential of lithium brines and other precious metals that demonstrate high probability for near-term production. The Company is currently concentrating on their Western Canada property. Founded in 2006, Lithium Exploration lists on the OTC Markets: OTCQB.
Lithium is a silver-white, lightweight, heat-resistant metal. It has other properties that also make it ideal for rechargeable batteries - offering higher power and lower self-discharge rates than other chemical materials. Lithium can be found in brines, clays and hard pegmatitic rock. However, the brines - such as the deposits mined by Lithium Exploration - offer a major cost advantage by a factor of approximately two or more. In addition to property with high lithium content in Canada, Lithium Exploration has connections to ready markets for their product - some of the largest manufacturers of lithium-based battery products in China and India.
Lithium Exploration's Valleyview Project is in northwest Alberta. The Project is 650,000 acres and there are more than 120 active wells. The Company has 100 percent mineral rights to the property. Sample testing conducted in 2011 showed 70 - 85 ppm lithium. Other minerals include calcium, magnesium, iodine, bromine, and potassium.
On March 17, 2011, the Company entered into a letter agreement between Lithium Exploration Group and Glottech-USA, LLC, for an acquisition of one initial unit of certain proprietary and patented mechanical ultrasound technology. This technology is for use in water treatment pertaining to their lithium operations in Alberta.
On November 8, 2011, they entered into a letter agreement with Glottech-USA. With this agreement, they were granted an exclusive license to use and distribute the technology within the Swan Hills region of Alberta as well as a non-exclusive right to distribute the technology within Canada. The design of the technology is to separate suspended solids from water (brine). This is one step in the process that Lithium Exploration is taking to produce commercially viable minerals.
Today, Lithium Exploration Group updated shareholders on the results of the most recent round of tests of the Company's ultrasonic generator. They resolved the power regulation issues and, over the first week of testing, the unit was ramped up to 70 percent of its target RPM; performance data was monitored and recorded. The inventor of the technology, Mr. Victor Glotov, arrived on Friday, December 7, 2012 and was able to observe the unit to review the pressure, torque, flow rates, temperature rise, and sound waves. Mr. Glotov confirmed that cavitation was occurring in the reaction chamber by measuring the frequency of the sound waves.
Lithium Exploration Group, Inc. (LEXG), closed Friday's trading session at $0.26, up 0.04%, on 38,554 volume with 20 trades. The average volume for the last 60 days is 179,049 and the stock's 52-week low/high is $0.18/$1.20.
Alderon Iron Ore Corp. (AXX)
Today we are reporting on Alderon Iron Ore Corp. (AXX), here at the QualityStocks Daily Newsletter.
Listed on the NYSE Market, Alderon Iron Ore Corp. is a leading iron ore development company in Canada. The Company has an iron ore project located next to the mining towns of Wabush and Labrador City in Western Labrador, Canada. The 100 percent owned Kami Project is within Canada's premier iron ore district; four producing iron ore mines surround it. Alderon Iron Ore has offices in Vancouver, Toronto, Montreal, Labrador City and St. John's.
The Kami Project currently hosts an NI 43-101 Mineral Resource estimate of 1.1 billion tonnes Measured and Indicated at 29.8 percent iron and an additional 277.4 million tonnes Inferred at 29.5 percent iron. Mineral resources that are not mineral reserves do not have demonstrated economic viability. Based on the Rose Central Preliminary Economic Assessment (PEA), Alderon's plan is to begin commercial production at a rate of 8 million tonnes annually at a grade of 65.5 percent iron.
The Kami property includes 305 claims in Labrador for a total of 7,625 hectares. Kami is within close proximity to a road, a common carrier railway, and a hydro power station. The multi-user railway will transport the material to a deep-sea port that will provide year round access to the global market.
Yesterday, the Company announced that they entered into an agreement with Nalcor Energy. Nalcor will perform Stage III engineering and assessment related to providing transmission and electrical plant and services associated with supplying electrical power for Alderon's Kami Project. Nalcor Energy has their headquarters in St. John's, Newfoundland and Labrador.
Alderon and Nalcor completed Stages I and II of the process. With the signing of the Agreement, Stage III started and the expectation is that it will take 6-8 months to conclude. Alderon funded all of the costs associated with Stage II and will fund all Stage III costs, estimated to be $3.8 million. Commercial discussions will begin during Stage III of the process. Once they agree on commercial terms, Alderon and Nalcor will sign a formal Power Purchase Agreement (PPA) subject to environmental and regulatory approvals.
Alderon Iron Ore Corp. (AXX), closed Friday's trading session at $1.67, up 7.04%, on 50,900 volume with 129 trades. The average volume for the last 60 days is 15,943 and the stock's 52-week low/high is $1.12/$3.83.
Trunity Holdings, Inc. (TNTY)
We are highlighting Trunity Holdings, Inc. (TNTY) today, here at the QualityStocks Daily Newsletter.
Listed on the OTC Bulletin Board, Trunity Holdings, Inc. is a leading provider of eLearning content and solutions. The Company's clients include higher education, K-12, and healthcare as well as other leading organizations. Trunity has personnel in the U.S., Canada, Russia, and India. Founded in 2009, The Company is based in Newburyport, Massachusetts.
Using the Trunity Platform, organizations can create content fast and easily to meet the specific requirements of particular educational environments. They can also share peer-reviewed, expert content as complete textbooks or curate portions into materials suited to their specific academic requirements. They can do this utilizing Live Cross Publishing and the Trunity Learning Exchange. Furthermore, they can collaborate and learn in a social learning environment that provides the ability for students to interact with each other and educators to enhance the learning experience.
Trunity has assembled a leadership team with an extensive amount of professional, scientific, internet media, and engineering expertise. In addition, the Trunity expert network includes authors that provide content used by tens of thousands of Trunity users. Authoring with Trunity includes writers Authoring for Education, Authoring for Research & Development, and Authoring for Enterprises. Market Solutions include Trunity for Education, Trunity for Research & Development, Trunity for Pharmaceuticals, and Trunity for Enterprises.
The Company's services include comprehensive implementation services to ensure a client's projects are effective and meet their expectations. Services also include training, designed to ensure that an organization is up and running on the Trunity Platform with a minimal time investment. Moreover, Company services include support, to ensure that their partners and customers realize the most successful outcomes from their use of the Trunity Platform.
In November, Trunity announced the launching of their Indian distributor, Trunity India. This distributor will service customers in India, Burma, Pakistan, Bangladesh, Nepal, and Sri Lanka. With the establishment of Trunity India, Trunity is now poised to capitalize on the rapidly growing eLearning market in the region.
Trunity Holdings, Inc. (TNTY), closed Friday's trading session at $0.49, up 63.33%, on 853 volume with 1 trade. The average volume for the last 60 days is 1,132 and the stock's 52-week low/high is $0.29/$5.00.
ScripsAmerica, Inc. (SCRC)
OTCtipReporter, PennyStockScholar, and SmallCapInvestorDaily reported this month on ScripsAmerica, Inc. (SCRC), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
ScripsAmerica, Inc. delivers pharmaceutical products to a broad spectrum of end users across the health care industry through the largest pharmaceutical distributor in North America, McKesson Corp. End users include physicians' offices, retail pharmacies, long-term care sites, hospitals, and Government and home care agencies. ScripsAmerica provides a strong low cost system of broad base U.S. national marketing, sales, and distribution of generic Rx, branded Rx, OTC, nutraceuticals, and oral delivery OTC pharmaceuticals. ScripsAmerica is based in New Castle, Delaware. The Company's shares trade on the OTC Bulletin Board.
Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, as well as hormonal replacement drugs. ScripsAmerica's other customers include Cardinal Health, Curtis Pharmaceuticals, MedVet and the United States Veterans Administration.
For Consumers, the Company's mission is to provide them the same high quality pharmaceutical, vitamin, and nutritional supplements that they supply nationally to Hospitals & Nursing Homes. Concerning Pharmaceutical Contract Services, ScripsAmerica's service offering includes fulfilling prescription and OTC orders, labeling, packaging, and shipping.
Earlier in December, ScripsAmerica announced that their Chief Executive Officer, Mr. Bob Schneiderman, issued a very positive outlook for 2013. Mr. Schneiderman cited how the Company expects to finalize the pending acquisition of Marlex Pharmaceuticals and launch their RapiMed children's pain reliever during the first quarter. Management's goal is to implement a regional launch of the RapiMed product line shortly after the beginning of 2013. ScripsAmerica expects that the acquisition of their current packager, Marlex Pharmaceuticals, will immediately increase the Company's profits by 10 to 15 percent.
In November, ScripsAmerica announced that Marlex Pharmaceuticals renewed their pharmaceutical supply contract with national nursing home chain, GeriMed. The new agreement extends through September 2014. It can potentially generate $2 million in revenue for Marlex Pharmaceuticals, which ScripsAmerica plans to operate as a wholly owned subsidiary upon their acquisition being finalized.
ScripsAmerica, Inc. (SCRC), closed Friday's trading session at $0.30, even for the day, on 3,200 volume with 2 trades. The average volume for the last 60 days is 18,876 and the stock's 52-week low/high is $0.22/$0.51.
Tianyin Pharmaceutical Co., Inc. (TPI)
Ceocast News reported recently on Tianyin Pharmaceutical Co., Inc. (TPI), PennyTrader Publisher, HEROSTOCKS, Liquid Pennies, Stockhunter.us did earlier, and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Based in Chengdu, China, Tianyin Pharmaceutical Co., Inc. is an enterprise that specializes in the development, manufacturing, marketing, and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics, and other pharmaceuticals. Presently, they manufacture a comprehensive portfolio of 58 products, 24 of which have listing in the highly selective National Medicine Reimbursement List (NMRL); 7 are included in the Essential Drug List (EDL) of China. The Company's shares trade on the NYSE Market.
Tianyin Pharmaceutical's products address major medical needs in the therapeutic areas spanning internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, orthopedics, dermatology, pediatrics, among others. Approximately half of their products are prescription medicines; the remaining is intended for Over-The-Counter (OTC) sales.
Tianyin Pharmaceutical's pipeline targets an array of high incidence healthcare indications. The Company has two state-of-the-art manufacturing facilities. In addition, the Company has an extensive nationwide sales and distribution network throughout China. Their pipeline consists of a number of late stage product candidates pending approval by the State Food and Drug Administration (SFDA) in China.
The Company focuses their research and development (R&D) efforts on new and innovative products with substantial market potential, as well as enhancement of existing products. Tianyin has formed R&D collaboration partnerships with some of the most prestigious research and development institutions in China. These include China Pharmaceutical University, Sichuan University-affiliated West China Center of Medical Sciences, and Shaanxi University of Chinese Medicines.
Recently, Tianyin Pharmaceutical announced financial results for the first quarter of fiscal year 2013. First Quarter Fiscal Year 2013 ended September 30, 2012 financial highlights include Revenue of $16.0 million compared with $17.5 million in 1Q12. Operating income was $2.2 million, compared with $2.1 million in 1Q12. Net Income was $1.5 million compared with $1.5 million in 1Q12.
The Company had Earnings per Share of $0.05 per basic share, and $0.05 per diluted share, compared with $0.05 per basic share, or $0.05 per diluted share in 1Q12. Cash and cash equivalents totaled $37.5 million on September 30, 2012; Operating cash flow for the quarter ended September 30, 2012 was $0.5 million, compared with $3.6 million for the quarter ended September 30, 2011.
Tianyin Pharmaceutical Co., Inc. (TPI), closed Friday's trading session at $0.64, up 1.59%, on 104,600 volume with 91 trades. The average volume for the last 60 days is 40,211 and the stock's 52-week low/high is $0.25/$0.894.
Cornerstone Capital Resources, Inc. (CGP.V)
London Irvine Report and Stockhouse reported previously on Cornerstone Capital Resources, Inc. (CGP.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Cornerstone Capital Resources Inc. is a mineral exploration company whose shares trade on the TSX Venture Exchange. The Company has a diversified portfolio of projects in Canada, Ecuador and Chile. The basis of their business model is on generating exploration projects whose subsequent development is funded primarily through Joint Venture (JV) partnerships. Cornerstone has their headquarters in Mount Pearl, Newfoundland and Labrador, Canada.
The Company has a diversified portfolio of gold, silver, copper, nickel, VMS, rare earth elements, and uranium properties in the aforementioned countries. Cornerstone has a diversified portfolio of early-stage exploration projects in Labrador with the potential for hosting deposits of rare earth elements (REE), uranium, nickel and gold.
Cornerstone is exploring for gold, volcanogenic massive sulphide (VMS) copper and zinc, and Sediment-Hosted Stratiform Copper (SSC) deposits on the island of Newfoundland. Currently, the Company's focus on the island is their Little Deer Copper Property, a 50/50 JV with Thundermin Resources, Inc. Additionally, Cornerstone is exploring for Volcanic-Associated Uranium and Sediment-Hosted Stratiform Copper (SSC) deposits in northern and southern New Brunswick, respectively.
Cornerstone's two most recent acquisitions are the Miocene and La Fortuna projects in Chile. They made these acquisitions through their wholly owned subsidiary Minera Cornerstone Chile Limitada (MCCL). Cornerstone has been exploring in Ecuador since 2005 via their wholly owned subsidiary, Cornerstone Ecuador S.A. Since that time, the Company has acquired 493 km2 of mineral rights that they believe offer significant potential for the discovery of epithermal gold-silver and porphyry copper-gold deposits.
Today, Cornerstone Capital Resources announced that they received formal notification from Intrepid Mines Ltd. that they are terminating with immediate effect the Call Option Agreement between Cornerstone and Intrepid dated January 4, 2011 for the Shyri gold/copper property in Ecuador. Cornerstone will review their options concerning Shyri and make a further announcement after that review has concluded.
Cornerstone Capital Resources, Inc. (CGP.V), closed Friday's trading session at $0.04, down 20.00%, on 169,349 volume. The stock's 52-week low/high is $0.03/$0.17.
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.054, up 8.00%, on 111,210 volume with 7 trades. The stock’s average daily volume over the past 60 days is 45,529, and its 52-week low/high is $0.0069/$0.07.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount Systems Appoints Dennis Raefield as Chief Operating Officer
Viscount Announces Completion of $500,000 Private Placement
Viscount Systems Wins Contract with Phoenix Sky Harbor Sky Train
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.749, up 7.00%, on 1,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 1,548, and its 52-week low/high is $0.06/$3.15.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium
VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™
VistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
The Guitammer Company Inc. (GTMM)
The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.16, up 6.67%, on 63,000 volume with 12 trades. The stock’s average daily volume over the past 60 days is 11,439, and its 52-week low/high is $0.082/$0.35.
The Guitammer Company Inc. (GTMM) is a leader in low-frequency sound products and technology. The company’s award-winning line of patented ButtKicker brand audio transducers let users actually feel the excitement, impacts, special effects, and bone-rattling bass brought by its immersive “4D” patent-protected technology. Guitammer’s products are well known for being musically accurate, powerful, and virtually indestructible.
The Guitammer Company was founded in 1990 by Ken McCaw, an accomplished musician, composer, and producer. Joining forces with Marvin Clamme, former sound engineer for Tom Jones and Merle Haggard, Ken and Marvin developed the original ButtKicker transducer prototypes in 1994.
Today, the ButtKicker brand products are used around the world by leading entertainment and theater companies, including AMC, IMAX, and Disney, in movie theaters and attractions. 85 entertainment locations in 11 countries have incorporated ButtKicker products to-date, providing the ultimate experience to over 10,000 seats. The products are also used in home theaters, simulators, and car audio applications.
Guitammer’s technology is compatible to virtually any digital source, including cable, satellite, fiber optic, IPTV, “over-the-air” broadcast, video games, and audio CDs. The ButtKicker brand products add unparalleled realism and excitement to movies, music, and games. Guitammer’s low-frequency, high-impact sound innovation is the next logical step after HDTV, 3DTV, and TiVo, bringing ground-breaking changes in how consumers enjoy their entertainment. Disclaimer
The Guitammer Company Inc. Company Blog
The Guitammer Company Inc. News:
Guitammer Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
Guitammer Third Quarter Revenue More Than Triples To $555,000
Guitammer CEO Mark Luden to Present at 7th Annual Singular Research 'Best of the Uncovereds' Conference in Los Angeles
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $9.05, up 0.11%, on 42,192 volume with 42 trades. The stock’s average daily volume over the past 60 days is 44,724, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
XOMA, a leader in the discovery and development of therapeutic antibodies, announced that Mr. Joseph M. Limber has been appointed to its Board of Directors.
“I am pleased to welcome Joe to our Board of Directors,” remarked John Varian, XOMA’s Chief Executive Officer. “Our team is particularly excited to work closely with Joe, as he has successfully developed markets for specialty pharmaceutical products and managed the critical transition from research organization to commercial entity. We expect to make the same transition in the coming years and Joe’s insight and guidance while we prepare for a gevokizumab commercial launch will be instrumental to our future success.”
With a career that spans over 30 years, Mr. Limber brings unparalleled biotechnology and corporate leadership experience to the Board. His current position as President and CEO at Prometheus Laboratories, a Nestle Health Science company, has positioned him to bring a new and unique perspective to XOMA’s board.
In the almost 10 years he has spent with Prometheus, Mr. Limber led a significant expansion of its business, both organically through internally developed products and through product acquisitions. He led negotiations to acquire exclusive U.S. commercial rights to ENTOCORT EC from AstraZeneca and Proleukin from Novartis, as well as the purchase of Lotronex from GlaxoSmithKline. Mr. Limber’s leadership helped Prometheus Laboratories grow its revenues to over $500 million.
Prior to Prometheus, Mr. Limber was a consultant and interim CEO of Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. He also served as President and CEO of ACLARA BioSciences, Inc., a developer of assay technologies and lab-on-a-chip systems for life science research, for four years, from 1998-2002. From 1996 to 1998, he was the President and COO of Praecis Pharmaceuticals, a biotechnology company focused on the discovery and development of pharmaceutical products.
Mr. Limber also served as Executive Vice President of SEQUUS Pharmaceuticals, Inc., in addition to management positions in marketing and sales with Syntex Corporation and with Ciba-Geigy Corporation. Mr. Limber has held seats on the Boards of Directors at numerous companies, including Panacos Pharmaceuticals, Molecular Insight Pharmaceuticals, and CombiMatrix Corporation.
For more information, visit www.XOMA.com
Amarantus BioScience has licensed the LymPro Alzheimer’s Disease Diagnostic Blood Test from Memory Dx LLC (MDx), growing Amarantus’ existing diagnostic pipeline and positioning the company to participate in related future opportunities.
LymPro, designed to diagnose Alzheimer’s in its mild to moderate stage, has completed two phase 1 clinical studies and is ready to move into a phase 2 validation study. If successful, Amarantus anticipates that LymPro can begin generating revenue as a laboratory-developed test within 18 months of study initiation, through commercial sales and sales to companies performing Alzheimer’s disease clinical research.
“We believe LymPro has significant clinical and commercial potential as a diagnostic blood test for Alzheimer’s disease,” Gerald E. Commissiong, president and CEO of Amarantus stated in the press release. “It is clear that the path forward for treating Alzheimer’s disease is to identify and initiate therapeutic intervention as early as possible. If proven effective, LymPro could provide physicians with a lower-cost, minimally-invasive intervention and reduce the need for costly brain imaging scans. This license expands our diagnostic pipeline and complements our strategic focus on neurodegenerative diseases. While we are not currently developing MANF for Alzheimer’s disease, we believe that the cost-effective definitive identification of earlier-stage patients will create a significant opportunity for Amarantus to evaluate the MANF Program as a disease-modifying treatment in this large, underserved therapeutic indication.”
Per the agreement, Amarantus will issue 2 million shares of restricted common stock to MDx, pay a development milestone upon successful completion of the phase 2 validation study, as well as pay a 9 percent royalty on sales.
Also as part of the deal, Amarantus will collaborate with MDx to perform the necessary validation study to gain Clinical Laboratory Improvement Amendments (CLIA) certification for LymPro. The companies’ strategy also includes strengthening and leveraging their relationships with large pharmaceutical companies and obtaining additional grant funding for the further development of LymPro.
“Amarantus represents an excellent partner for Memory Dx because of its scientific focus on protein misfolding and aggregation, which we believe will continue to be critical in developing disease-modifying treatments for Alzheimer’s,” said William E. Gartner, president and CEO of MDx. “This agreement with Amarantus is the final step in the transition of Memory Dx from a diagnostic product developer into a contract CLIA lab focused on driving revenues. We look forward to working with Amarantus to advance LymPro and get it into the hands of physicians so we can help address the significant socioeconomic problems caused by Alzheimer’s disease.”
For more information, visit www.Amarantus.com
Alexza Pharmaceuticals and Grupo Ferrer Interncional, S.A., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending that ADASUVE (Staccato loxapine) be granted European Union (EU) centralized marketing authorization. The CHMP recommends that ADASUVE be authorized in the EU for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The recommendation by the CHMP is that ADASUVE should be administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects, such as bronchospasm.
Alexza’s clinical development program can be credited as the basis for the positive opinion. The program included two randomized, multicenter Phase 3 pivotal studies of ADASUVE, which enrolled 344 adult patients with schizophrenia and 314 adult patients with bipolar disorder. Each of the trials displayed statistically significant reductions in agitation from baseline compared to placebo. In the EU alone, an estimated 8 million adults suffer from schizophrenia or bipolar disorder and a common symptom for these patients is agitation.
“The recommendation for approval from CHMP moves us one step closer to bringing this novel treatment to patients with agitation,” said James V. Cassella, PhD, Executive Vice President and Chief Scientific Officer, Alexza Pharmaceuticals. “We believe that ADASUVE may provide an important new therapeutic option as the first rapid and non-invasive treatment to address episodes of agitation.”
The European Commission (EC) will now receive the positive opinion from the CHMP, and the EC has the authority to award marketing authorization for medicinal products in the European Union. The European Commission is expected to grant the marketing authorization to Alexza, and the authorization will be applicable in all 27 EU Member States, plus Iceland, Liechtenstein and Norway. The EC is expected to render a decision in the first quarter of 2013. Alexza initialy filed the ADASUVE Marketing Authorization Application (MAA) with EMA in October 2011.
For further information, visit www.alexza.com
Advanced Medical Isotope, a company engaged in the production and distribution of medical isotopes, is pleased to announce a recent strategic alliance with Safety by Design, PC, of Colorado, in collaboration with Colorado State University.
The strategic partnership was formed to develop medical isotope products that are in high demand and short supply in the Rocky Mountain Region while developing production processes and procedures to produce isotope products using the 1 megawatt TRIGA Reactor currently operating at the Denver Federal Center. This project site is ideally located geographically, minutes from Denver International Airport and two other General Aviation airports, making the site an optimal location regionally for the production and distribution of short-lived radionuclides.
The initial production will focus on a skin cancer product (Ho-166), then utilizing the same isotope, the partnership plans to develop products for the treatment of joint pain, liver cancer, and multiple myeloma.
James C. Katzaroff, Chairman and CEO of AMIC, said, “AMIC has been studying the Rocky Mountain Region for expansion for several years and we look forward to a successful partnership with Safety by Design.”
Further, a long term goal for AMIC and Safety by Design is to create an isotope production roadmap for other TRIGA reactor facilities in the United States and expand the breadth of relevant chemical separation methods while evaluating health physics operational procedures for facilities with less sophisticated isotope handling capabilities. The partnership is also developing training materials and expertise that is necessary to prepare the next generation for future domestic isotope production.
“We are excited to team with AMIC on this tremendously important project to bring urgently needed radiopharmaceutical products to the medical community,” stated Ken Pethe, President of Safety by Design, PC.
Today's Top 3
The Stock Psycho
The QualityStocks Public Company Sponsor News